Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 5,200 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 5,200 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the sale, the senior vice president now directly owns 98,519 shares of the company’s stock, valued at approximately $2,318,152.07. This represents a 5.01 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Travere Therapeutics Stock Performance

TVTX opened at $23.20 on Thursday. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The business has a 50 day simple moving average of $19.06 and a two-hundred day simple moving average of $15.95. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Hedge Funds Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in Travere Therapeutics by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 1,842,301 shares of the company’s stock valued at $32,100,000 after purchasing an additional 111,256 shares during the period. Franklin Resources Inc. bought a new stake in shares of Travere Therapeutics during the 4th quarter valued at about $631,000. Wellington Management Group LLP purchased a new position in shares of Travere Therapeutics during the fourth quarter valued at about $583,000. Norges Bank purchased a new position in shares of Travere Therapeutics during the fourth quarter valued at about $1,237,000. Finally, EntryPoint Capital LLC bought a new position in Travere Therapeutics in the fourth quarter worth about $359,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TVTX shares. Scotiabank boosted their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Wednesday. HC Wainwright boosted their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Piper Sandler raised their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $9.00 to $27.00 in a report on Monday, October 21st. Finally, Barclays increased their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.